Goldman Sachs
CODX

Goldman Sachs’s Co-Diagnostics CODX Stock Holding History

Goldman Sachs’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-434
Closed -$4.03K – 6118
2025
Q1 		$4.03K Sell
434
-99
-19% -$1.89K ﹤0.01% 5994
2024
Q4 		$12K Buy
+533
New +$16.8K ﹤0.01% 5928
2022
Q1 		– Sell
-2,850
Closed -$763K – 6603
2021
Q4 		$763K Buy
2,850
+1,156
+68% +$303K ﹤0.01% 5068
2021
Q3 		$494K Buy
1,694
+731
+76% +$213K ﹤0.01% 5203
2021
Q2 		$238K Buy
963
+583
+153% +$150K ﹤0.01% 5654
2021
Q1 		$109K Buy
+380
New +$152K ﹤0.01% 5820
2020
Q4 		– Sell
-1,566
Closed -$638K – 5511
2020
Q3 		$638K Buy
1,566
+378
+32% +$194K ﹤0.01% 4349
2020
Q2 		$689K Buy
1,188
+174
+17% +$79.4K ﹤0.01% 4198
2020
Q1 		$232K Buy
+1,014
New +$176K ﹤0.01% 4636

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's CODX Position: Q2 2025 in Review

Goldman Sachs sold out of Co-Diagnostics (CODX) in Q2 2025, closing a stake of 434 shares — an estimated $4.03K sold.

Goldman Sachs first reported a position in CODX in Q1 2020 and held it in 9 quarters. The position peaked at $763K in Q4 2021. 35 funds tracked by Wall St. Rank hold CODX as of Q2 2025.

  • Goldman Sachs reported no remaining Co-Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 434 Co-Diagnostics shares in Q2 2025, an estimated $4.03K.
  • Goldman Sachs first reported a position in Co-Diagnostics in Q1 2020 and held it in 9 quarters.
  • Goldman Sachs's Co-Diagnostics position peaked at $763K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.